NASDAQ:HCM - HUTCHISON CHINA/S Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $25.70 +0.65 (+2.59 %) (As of 02/19/2019 08:35 AM ET)Previous Close$25.05Today's Range$24.93 - $25.7152-Week Range$20.83 - $39.68Volume96,580 shsAverage Volume149,673 shsMarket Capitalization$3.42 billionP/E Ratio-116.82Dividend YieldN/ABeta1.01 ProfileDiscussionAnalyst RatingsChartFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments. The company discovers and develops therapeutics in oncology and autoimmune diseases, as well as provides research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical drug candidates include Savolitinib, an inhibitor for treating non-small cell lung, colorectal, and gastric cancer, as well as papillary renal cell carcinoma; Fruquintinib, an oral inhibitor for the treatment of colorectal, non-small cell lung, and gastric cancer; Sulfatinib for treating neuroendocrine tumors, and thyroid and biliary tract cancer; and Epitinib for the treatment of non-small cell lung cancer, as well as for patients with glioblastoma. The company also develops Theliatinib epidermal growth factor receptor inhibitor for treating solid tumors, as well as for patients with esophageal cancer; HMPL-523, an oral inhibitor for the treatment of immunology, rheumatoid arthritis, and hematological cancers; HMPL-689, a small molecule inhibitor for the treatment of hematologic cancers, autoimmunity and transplant organ rejection, and other related inflammation diseases; HMPL-453, a small molecule inhibitor for the treatment of solid tumors; and HMPL-004 for the treatment of ulcerative colitis and Crohn's disease. It has strategic alliances with AstraZeneca AB (publ); Eli Lilly and Company; and Nestlé Health Science SA. The company was founded in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited. Receive HCM News and Ratings via Email Sign-up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HCM Previous Symbol CUSIPN/A Webwww.chi-med.com Phone852-2121-3888Debt Debt-to-Equity Ratio0.06 Current Ratio4.67 Quick Ratio4.55Price-To-Earnings Trailing P/E Ratio-116.82 Forward P/E Ratio-42.83 P/E GrowthN/A Sales & Book Value Annual Sales$241.20 million Price / Sales14.17 Cash FlowN/A Price / Cash FlowN/A Book Value$3.65 per share Price / Book7.04Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees590 Outstanding Shares132,950,000Market Cap$3.42 billion OptionableNot Optionable HUTCHISON CHINA/S (NASDAQ:HCM) Frequently Asked Questions What is HUTCHISON CHINA/S's stock symbol? HUTCHISON CHINA/S trades on the NASDAQ under the ticker symbol "HCM." When is HUTCHISON CHINA/S's next earnings date? HUTCHISON CHINA/S is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for HUTCHISON CHINA/S. Has HUTCHISON CHINA/S been receiving favorable news coverage? Media headlines about HCM stock have trended positive on Tuesday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. HUTCHISON CHINA/S earned a news impact score of 2.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. Who are some of HUTCHISON CHINA/S's key competitors? Some companies that are related to HUTCHISON CHINA/S include GRIFOLS S A/S (GRFS), Sarepta Therapeutics (SRPT), Genmab A/S (GNMSF), Bausch Health Companies (BHC), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Nektar Therapeutics (NKTR), Loxo Oncology (LOXO), Marina Biotech (MRNA), Perrigo (PRGO), Catalent (CTLT) and Dr.Reddy's Laboratories (RDY). Who are HUTCHISON CHINA/S's key executives? HUTCHISON CHINA/S's management team includes the folowing people: Mr. Chi Keung To BSc, ACGI, MBA, Exec. Chairman (Age 67)Mr. Christian Hogg BSc, MBA, CEO & Exec. Director (Age 53)Mr. Johnny Cheng BEc, CA, CFO & Exec. Director (Age 52)Dr. Weiguo Su Ph.D., Chief Scientific Officer, Exec. VP & Exec. Director (Age 62)Ms. Edith Shih B.S., M.A., BSE, MA, EdM, Solicitor, FCIS, FCS(PE), Company Sec. & Non-Exec. Director (Age 67) When did HUTCHISON CHINA/S IPO? (HCM) raised $100 million in an IPO on Thursday, March 17th 2016. The company issued 6,100,000 shares at a price of $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities acted as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers. Who are HUTCHISON CHINA/S's major shareholders? HUTCHISON CHINA/S's stock is owned by many different of retail and institutional investors. Top institutional investors include Prudential PLC (3.09%), BlackRock Inc. (2.36%), Bellevue Group AG (0.33%), Karst Peak Capital Ltd (0.17%), Northern Trust Corp (0.16%) and Baillie Gifford & Co. (0.15%). Which institutional investors are selling HUTCHISON CHINA/S stock? HCM stock was sold by a variety of institutional investors in the last quarter, including Karst Peak Capital Ltd and Prudential PLC. Which institutional investors are buying HUTCHISON CHINA/S stock? HCM stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Northern Trust Corp, Bank of America Corp DE, Legal & General Group Plc, Geode Capital Management LLC, Amundi Pioneer Asset Management Inc., Canada Pension Plan Investment Board and Bank of New York Mellon Corp. How do I buy shares of HUTCHISON CHINA/S? Shares of HCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is HUTCHISON CHINA/S's stock price today? One share of HCM stock can currently be purchased for approximately $25.70. How big of a company is HUTCHISON CHINA/S? HUTCHISON CHINA/S has a market capitalization of $3.42 billion and generates $241.20 million in revenue each year. The company earns $-26,730,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis. HUTCHISON CHINA/S employs 590 workers across the globe. What is HUTCHISON CHINA/S's official website? The official website for HUTCHISON CHINA/S is http://www.chi-med.com. How can I contact HUTCHISON CHINA/S? HUTCHISON CHINA/S's mailing address is 22ND FLOOR HUTCHISON HOUSE 10 HARCOURT ROAD, HONG KONG K3, . The company can be reached via phone at 852-2121-3888 or via email at [email protected] MarketBeat Community Rating for HUTCHISON CHINA/S (NASDAQ HCM)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 193 (Vote Outperform)Underperform Votes: 162 (Vote Underperform)Total Votes: 355MarketBeat's community ratings are surveys of what our community members think about HUTCHISON CHINA/S and other stocks. Vote "Outperform" if you believe HCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HCM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/19/2019 by MarketBeat.com StaffFeatured Article: What is a back-end load?